Benzinga ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
ANI Pharma beats Q4 estimates, swings to profit, and sees over $1 billion in 2026 sales as Rare Disease revenue surges 50%. Importance Rank: 1 read more
ANI Pharma beats Q4 estimates, swings to profit, and sees over $1 billion in 2026 sales as Rare Disease revenue surges 50%. Importance Rank: 1 read more